

Product Data Sheet

Product Name: CD532
Cat. No.: GC48982

Chemical Properties

Cas. No. 1639009-81-6

SMILES O=C(NC1=CC=CC(C(F)(F)F)=C1)NC2=CC=C(NC3=NC(NC4=NNC(C5CCCC5)=C4)=C=N3)C=C2


Formula C₂₆H₂₅F₃N₈O M.Wt 522.5

Solubility Ethanol: soluble Storage -20°C

General For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the tips ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Evaluation sample solution : ship with blue ice All other available size: ship with RT, or Condition blue ice upon request.

Structure



Background

CD532 is an inhibitor of Aurora A kinase activity (IC₅₀ = 48 nM) and the protein-protein interaction between N-Myc and Aurora A kinase.¹ It also inhibits several cyclin-dependent kinases (CDKs), FGFRs, MEKs, and PDGFRs, as well as FLT3, KIT, and RET at 10 μM.² CD532 induces degradation of N-Myc in SK-N-BE(2) neuroblastoma cells (EC₅₀ = 223 nM).¹ It prevents S-phase entry in SK-N-BE(2) cells when used at a concentration of 1 μM.¹ CD532 (25 mg/kg) reduces tumor growth and increases survival in a MYCN-amplified SMS-KCN neuroblastoma mouse xenograft model.

1. Gustafson, W.C., Meyerowitz, J.G., Nekritz, E.A., et al. Drugging MYCN through an allosteric transition in Aurora kinase A. *Cancer Cell* 26(3):414-427 (2014)
2. Lee, J.K., Phillips, J.W., Smith, B.A., et al. N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. *Cancer Cell* 29(4):536-547 (2016)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA